Breaking through convention to simplicity in type 2 diabetes care
Two case studies are briefly presented, providing clinical guidance on the intensification of insulin therapy
Learning objectives:
- The discussion covers key aspects of clinical interest when introducing iGlarLixi, including therapy acceptability, potential adverse effects, and other relevant issues based on the presenters’ extensive experience.
- The benefits of using fixed-dose combination insulin/GLP-1 agonist therapy to reduce complications of type 2 diabetes mellitus (T2DM)
- Factors that influence HbA1c treatment targets, the benefits and drawbacks of different diabetes medications in achieving target, and the manner of safely initiating iGlarLixi therapy to optimise
therapeutic efficacy - An approach to the management of a patient with comorbid dyslipidaemia, hypertension, chronic
kidney disease and ischaemic heart disease
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.
To access this module, please register or login: